Actively Recruiting
Biomarkers of Depression and Treatment Response
Led by University of California, San Francisco · Updated on 2026-01-30
50
Participants Needed
1
Research Sites
352 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a stratified, parallel-group, single-center study utilizing multimodal imaging techniques to identify biomarkers for Major Depressive Disorder (MDD). The study goal is to identify biomarkers for MDD and treatment response that can be implemented in clinical diagnosis and care as valid and reliable measures, through monitoring neurophysiological and electrophysiological changes across the course of transcranial magnetic stimulation (TMS) treatment.
CONDITIONS
Official Title
Biomarkers of Depression and Treatment Response
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-70
- Diagnosed with Major Depressive Disorder in a current major depressive episode without psychotic features
- Montgomery-Asberg Depressive Rating Scale (MADRS) score greater than 19 at baseline indicating moderate to severe depression
- Moderate resistance to antidepressant treatment in the current episode, defined as failure of 1-4 adequate medication trials
- No changes to psychotropic medication regimen between pre-treatment and post-treatment scans if currently taking medication
- Willing and able to undergo non-invasive brain stimulation
- Willing and able to attend research visits for approximately 8 weeks
- Able to provide informed consent
- Able to speak and read English
You will not qualify if you...
- Diagnosis of acute or chronic psychotic symptoms or psychotic disorders during the current depressive episode
- Neurological conditions including epilepsy, cerebrovascular disease, dementia, increased intracranial pressure, history of severe head trauma, or brain tumors
- Presence of implanted magnetic-sensitive medical devices near the head (e.g., pacemaker, vagus nerve stimulator, metal clips, coils, staples, or stents)
- Generalized anxiety disorder as the primary diagnosis during the current MDD episode
- Alcohol or substance abuse or dependence (other than caffeine) within the past 6 months
- History of seizures
- Implantable hardware not compatible with MRI or study requirements
- Inability to comply with daily study visits
- Women who are pregnant, planning pregnancy, or breastfeeding
- Inability to speak and/or read English
- Inability to give informed consent
- Active suicidal intent or plan during the current episode as determined by standardized assessments or clinical judgment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
K
Katherine Scangos, MD, PhD
CONTACT
R
Rebecca Martinez, MS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here